1. Home
  2. SKYE vs INTT Comparison

SKYE vs INTT Comparison

Compare SKYE & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • INTT
  • Stock Information
  • Founded
  • SKYE 2012
  • INTT 1981
  • Country
  • SKYE United States
  • INTT United States
  • Employees
  • SKYE N/A
  • INTT N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • INTT Semiconductors
  • Sector
  • SKYE Health Care
  • INTT Technology
  • Exchange
  • SKYE Nasdaq
  • INTT Nasdaq
  • Market Cap
  • SKYE 80.7M
  • INTT 77.3M
  • IPO Year
  • SKYE N/A
  • INTT 1997
  • Fundamental
  • Price
  • SKYE $1.81
  • INTT $6.11
  • Analyst Decision
  • SKYE Buy
  • INTT Strong Buy
  • Analyst Count
  • SKYE 6
  • INTT 2
  • Target Price
  • SKYE $16.60
  • INTT $12.00
  • AVG Volume (30 Days)
  • SKYE 1.7M
  • INTT 36.7K
  • Earning Date
  • SKYE 05-08-2025
  • INTT 05-02-2025
  • Dividend Yield
  • SKYE N/A
  • INTT N/A
  • EPS Growth
  • SKYE N/A
  • INTT N/A
  • EPS
  • SKYE N/A
  • INTT N/A
  • Revenue
  • SKYE N/A
  • INTT $127,503,000.00
  • Revenue This Year
  • SKYE N/A
  • INTT $1.65
  • Revenue Next Year
  • SKYE N/A
  • INTT $7.63
  • P/E Ratio
  • SKYE N/A
  • INTT N/A
  • Revenue Growth
  • SKYE N/A
  • INTT 5.19
  • 52 Week Low
  • SKYE $1.14
  • INTT $5.24
  • 52 Week High
  • SKYE $13.49
  • INTT $11.92
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 48.48
  • INTT 45.10
  • Support Level
  • SKYE $1.36
  • INTT $5.56
  • Resistance Level
  • SKYE $2.30
  • INTT $6.69
  • Average True Range (ATR)
  • SKYE 0.21
  • INTT 0.34
  • MACD
  • SKYE 0.02
  • INTT 0.07
  • Stochastic Oscillator
  • SKYE 42.35
  • INTT 48.67

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About INTT inTest Corporation

inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.

Share on Social Networks: